Hydrogel polymeric compositions and methods
First Claim
1. A method of treating an ophthalmic disease affecting an eye of a patient comprising forming a covalently-crosslinked hydrogel in situ at a site in an eye, wherein the hydrogel, when formed, has a volume of less than 0.5 ml and comprises a hydrophobic particle entrapped as a suspension within the hydrogel, the particle comprising a therapeutic agent that is released into the eye to treat the ophthalmic disease, wherein a time at which a cumulative 80% w/w of the therapeutic agent has been released is between about 14 and 120 days.
4 Assignments
0 Petitions
Accused Products
Abstract
Some aspects of this disclosure relate to a method of treating an ophthalmic disease affecting an eye of a patient comprising forming a covalently-crosslinked hydrogel in situ at a peri-ocular, intra-ocular, or intra-vitreal site for controlled release of a therapeutic agent.
-
Citations
21 Claims
- 1. A method of treating an ophthalmic disease affecting an eye of a patient comprising forming a covalently-crosslinked hydrogel in situ at a site in an eye, wherein the hydrogel, when formed, has a volume of less than 0.5 ml and comprises a hydrophobic particle entrapped as a suspension within the hydrogel, the particle comprising a therapeutic agent that is released into the eye to treat the ophthalmic disease, wherein a time at which a cumulative 80% w/w of the therapeutic agent has been released is between about 14 and 120 days.
Specification